30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

BioXcel Therapeutics Inc (BTAI)

Track

Over the last 90 days, BioXcel Therapeutics Inc. has seen 8 insider transactions, all of which were sales totaling $86,151.61. Notably, the CEO, CFO, and CSO have engaged in planned and proposed sales. The company's stock has experienced a 21.2% decrease in the last 90 days. The last earnings report missed expectations by 12.5%.
Stock chart
Ticker: BTAI Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Yocca Frank
Chief Scientific Officer
2 sales — total 14,857 USD
Planned sale 20 May 2026
Value US$4,008,015.52 | Price 12.19 | Shares 90,837
Proposed sale 20 May 2026
Value US$1,590,751.69 | Price 210.15 | Shares 36,981
Planned sale 20 May 2026
Value US$152,873.58 | Price 11.27 | Shares 10,704
Proposed sale 20 May 2026
Value US$1,606,537.42 | Price 57.50 | Shares 72,960
Planned sale 20 May 2026
Value US$7,426.82 | Price 1.09 | Shares 6,845
Proposed sale 20 May 2026
Value US$7,425.72 | Price 1.08 | Shares 6,845
Planned sale 20 May 2026
Value US$21,108.45 | Price 1.09 | Shares 19,419
Proposed sale 20 May 2026
Value US$21,113.72 | Price 1.09 | Shares 19,419
Planned sale 16 Dec 2024
Value US$58.13 | Price 0.35 | Shares 165
Proposed sale 16 Dec 2024
Value US$58.13 | Price 0.35 | Shares 165
Planned sale 16 Dec 2024
Value US$79.02 | Price 0.35 | Shares 225
Planned sale 16 Dec 2024
Value US$72.80 | Price 0.36 | Shares 205
Proposed sale 16 Dec 2024
Value US$151.82 | Price 0.35 | Shares 430
Planned sale 16 Dec 2024
Value US$773.36 | Price 0.36 | Shares 2,134
Planned sale 16 Dec 2024
Value US$357.91 | Price 0.36 | Shares 983
Proposed sale 16 Dec 2024
Value US$452.71 | Price 0.34 | Shares 1,315
Proposed sale 16 Dec 2024
Value US$340.00 | Price 0.35 | Shares 983
Planned sale 16 Dec 2024
Value US$78.47 | Price 0.36 | Shares 220
Planned sale 16 Dec 2024
Value US$74.55 | Price 0.36 | Shares 210
Proposed sale 16 Dec 2024
Value US$153.02 | Price 0.36 | Shares 430
Planned sale 16 Dec 2024
Value US$133.18 | Price 0.36 | Shares 372
Planned sale 16 Dec 2024
Value US$73.80 | Price 0.36 | Shares 205
Proposed sale 16 Dec 2024
Value US$154.35 | Price 0.36 | Shares 430
Proposed sale 16 Dec 2024
Value US$154.35 | Price 0.35 | Shares 438
Proposed sale 3 Oct 2024
Value US$3,775.74 | Price 0.55 | Shares 6,863
Planned sale 3 Oct 2024
Value US$3,774.65 | Price 0.55 | Shares 6,863
Proposed sale 3 Oct 2024
Value US$3,449.60 | Price 0.55 | Shares 6,272
Planned sale 3 Oct 2024
Value US$3,449.60 | Price 0.55 | Shares 6,272
Proposed sale 3 Oct 2024
Value US$3,055.82 | Price 0.55 | Shares 5,556
Planned sale 3 Oct 2024
Value US$3,055.80 | Price 0.55 | Shares 5,556
Proposed sale 3 Oct 2024
Value US$3,946.26 | Price 0.55 | Shares 7,175
Planned sale 3 Oct 2024
Value US$3,946.25 | Price 0.55 | Shares 7,175
Proposed sale 3 Oct 2024
Value US$3,946.59 | Price 0.55 | Shares 7,175
Planned sale 3 Oct 2024
Value US$3,946.25 | Price 0.55 | Shares 7,175
Planned sale 16 Sep 2024
Value US$794.08 | Price 0.69 | Shares 1,150
Planned sale 16 Sep 2024
Value US$572.83 | Price 0.69 | Shares 832
Proposed sale 16 Sep 2024
Value US$793.50 | Price 0.69 | Shares 1,150
Proposed sale 16 Sep 2024
Value US$574.08 | Price 0.69 | Shares 832
Planned sale 16 Sep 2024
Value US$245.60 | Price 0.69 | Shares 356
Proposed sale 16 Sep 2024
Value US$245.60 | Price 0.69 | Shares 356
Planned sale 16 Sep 2024
Value US$238.05 | Price 0.69 | Shares 345
Proposed sale 16 Sep 2024
Value US$238.05 | Price 0.69 | Shares 345
Planned sale 16 Sep 2024
Value US$148.52 | Price 0.69 | Shares 215
Proposed sale 16 Sep 2024
Value US$148.52 | Price 0.69 | Shares 215
Planned sale 16 Sep 2024
Value US$95.33 | Price 0.69 | Shares 138
Proposed sale 16 Sep 2024
Value US$95.33 | Price 0.69 | Shares 138
Planned sale 16 Sep 2024
Value US$244.70 | Price 0.69 | Shares 355
Proposed sale 16 Sep 2024
Value US$244.70 | Price 0.69 | Shares 355
Planned sale 17 Jun 2024
Value US$476.16 | Price 1.28 | Shares 372
Proposed sale 17 Jun 2024
Value US$476.16 | Price 1.28 | Shares 372
Planned sale 17 Jun 2024
Value US$456.02 | Price 1.26 | Shares 361
Proposed sale 17 Jun 2024
Value US$456.02 | Price 1.26 | Shares 361
Planned sale 17 Jun 2024
Value US$469.54 | Price 1.26 | Shares 372
Proposed sale 17 Jun 2024
Value US$469.54 | Price 1.26 | Shares 372
Planned sale 17 Jun 2024
Value US$2,738.99 | Price 1.28 | Shares 2,134
Proposed sale 17 Jun 2024
Value US$1,172.61 | Price 1.29 | Shares 909
Proposed sale 17 Jun 2024
Value US$1,428.75 | Price 1.17 | Shares 1,225
Planned sale 17 Jun 2024
Value US$308.10 | Price 1.26 | Shares 244
Proposed sale 17 Jun 2024
Value US$308.10 | Price 1.26 | Shares 244
Planned sale 17 Jun 2024
Value US$199.17 | Price 1.29 | Shares 155
Proposed sale 17 Jun 2024
Value US$199.18 | Price 1.29 | Shares 155
Sale 5 Jun 2024
Value US$199,618.78 | Price 1.58 | Shares 126,014
Sale 4 Jun 2024
Value US$205,516.23 | Price 1.63 | Shares 126,014
Proposed sale 4 Jun 2024
Value US$378,042.00 | Price 1.50 | Shares 252,028
Planned sale 4 Apr 2024
Value US$2,667.43 | Price 2.64 | Shares 1,012
Proposed sale 4 Apr 2024
Value US$2,661.82 | Price 2.63 | Shares 1,012
Planned sale 4 Apr 2024
Value US$2,816.82 | Price 2.64 | Shares 1,069
Proposed sale 4 Apr 2024
Value US$2,809.90 | Price 2.63 | Shares 1,069
Planned sale 4 Apr 2024
Value US$432.48 | Price 2.62 | Shares 165
Planned sale 4 Apr 2024
Value US$11,651.04 | Price 2.62 | Shares 4,439
Planned sale 4 Apr 2024
Value US$2,171.98 | Price 2.62 | Shares 829
Proposed sale 4 Apr 2024
Value US$11,650.90 | Price 2.62 | Shares 4,439
Planned sale 4 Apr 2024
Value US$2,811.54 | Price 2.64 | Shares 1,067
Planned sale 4 Apr 2024
Value US$2,656.18 | Price 2.64 | Shares 1,008
Proposed sale 4 Apr 2024
Value US$2,651.26 | Price 2.63 | Shares 1,008
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-22 2026-05-20 PlS Planned sale
2.3
Yocca Frank

Chief Scientific Officer

Officer
90,837 +19.0%
12.19
US$4,008,016 		90,837 +19.0% 12.19 US$4,008,016
2026-05-22 2026-05-20 PlS Planned sale
Rodriguez Javier

See Remarks

Officer
10,704 +38.9%
11.27
US$152,874 		10,704 +38.9% 11.27 US$152,874
2026-05-22 2026-05-20 PlS Planned sale
2.7
Steinhart Richard I

Chief Financial Officer

Officer
68,576 -4.2%
361.44
US$1,934,612 		68,576 -4.2% 361.44 US$1,934,612
2026-05-22 2026-05-20 PlS Planned sale
3.3
Mehta Vimal

CEO and President

Executive Director
19,419 -21.8%
1.09
US$21,108 		19,419 -21.8% 1.09 US$21,108
2026-05-20 2026-05-20 PrS Proposed sale
Rodriguez Javier

Officer

Officer
6,560
1.08
US$7,109 		6,560 1.08 US$7,109
2026-05-20 2026-05-20 PrS Proposed sale
3.3
Mehta Vimal

Officer

Officer
19,419
1.09
US$21,114 		19,419 1.09 US$21,114
2026-05-20 2026-05-20 PrS Proposed sale
2.3
Yocca Frank

Officer

Officer
6,845
1.09
US$7,430 		6,845 1.09 US$7,430
2026-05-20 2026-05-20 PrS Proposed sale
2.7
Steinhart Richard I

Officer

Officer
6,845
1.08
US$7,426 		6,845 1.08 US$7,426
2024-12-17 2024-12-16 PlS Planned sale
O'Neill Vincent

See Remarks

Officer
165 -0.8%
0.35
US$58 		165 -0.8% 0.35 US$58
2024-12-17 2024-12-16 PlS Planned sale
2.3
Yocca Frank

Chief Scientific Officer

Officer
225 -0.8%
0.35
US$79 		225 -0.8% 0.35 US$79
2024-12-17 2024-12-16 PlS Planned sale
2.3
Yocca Frank

Chief Scientific Officer

Officer
205 -0.7%
0.36
US$73 		205 -0.7% 0.36 US$73
2024-12-17 2024-12-16 PlS Planned sale
3.3
Mehta Vimal

CEO and President

Executive Director Large shareholder
2,134 -3.5%
0.36
US$773 		2,134 -3.5% 0.36 US$773
2024-12-17 2024-12-16 PlS Planned sale
3.3
Mehta Vimal

CEO and President

Executive Director Large shareholder
983 -1.6%
0.36
US$358 		983 -1.6% 0.36 US$358
2024-12-17 2024-12-16 PlS Planned sale
Rodriguez Javier

See Remarks

Officer
220 -0.9%
0.36
US$78 		220 -0.9% 0.36 US$78
2024-12-17 2024-12-16 PlS Planned sale
Rodriguez Javier

See Remarks

Officer
210 -0.8%
0.36
US$75 		210 -0.8% 0.36 US$75
2024-12-17 2024-12-16 PlS Planned sale
2.7
Steinhart Richard I

Chief Financial Officer

Officer
372 -1.7%
0.36
US$133 		372 -1.7% 0.36 US$133
2024-12-17 2024-12-16 PlS Planned sale
2.7
Steinhart Richard I

Chief Financial Officer

Officer
205 -1.0%
0.36
US$74 		205 -1.0% 0.36 US$74
2024-12-16 2024-12-16 PrS Proposed sale
O'Neill Vincent

Officer

Officer
165
0.35
US$58 		165 0.35 US$58
2024-12-16 2024-12-16 PrS Proposed sale
Rodriguez Javier

Officer

Officer
430
0.36
US$153 		430 0.36 US$153
2024-12-16 2024-12-16 PrS Proposed sale
2.7
Steinhart Richard I

Officer

Officer
430
0.36
US$154 		430 0.36 US$154
2024-12-16 2024-12-16 PrS Proposed sale
2.3
Yocca Frank

Officer

Officer
430
0.35
US$152 		430 0.35 US$152
2024-12-16 2024-12-16 PrS Proposed sale
2.7
Steinhart Richard I

Officer

Officer
438
0.35
US$154 		438 0.35 US$154
2024-12-16 2024-12-16 PrS Proposed sale
3.3
Mehta Vimal

Officer

Officer
1,315
0.34
US$453 		1,315 0.34 US$453
2024-12-16 2024-12-16 PrS Proposed sale
3.3
Mehta Vimal

Officer

Officer
983
0.35
US$340 		983 0.35 US$340
2024-10-03 2024-10-03 PrS Proposed sale
Rodriguez Javier

Officer

Officer
6,863
0.55
US$3,776 		6,863 0.55 US$3,776
2024-10-03 2024-10-03 PrS Proposed sale
Wiley Matthew T.

Officer

Officer
6,272
0.55
US$3,450 		6,272 0.55 US$3,450
2024-10-03 2024-10-03 PrS Proposed sale
O'Neill Vincent

Officer

Officer
5,556
0.55
US$3,056 		5,556 0.55 US$3,056
2024-10-03 2024-10-03 PrS Proposed sale
2.3
Yocca Frank

Officer

Officer
7,175
0.55
US$3,946 		7,175 0.55 US$3,946
2024-10-03 2024-10-03 PrS Proposed sale
2.7
Steinhart Richard I

Officer

Officer
7,175
0.55
US$3,947 		7,175 0.55 US$3,947
2024-10-03 2024-10-03 PlS Planned sale
O'Neill Vincent

See Remarks

Officer
5,556 -22.1%
0.55
US$3,056 		5,556 -22.1% 0.55 US$3,056
2024-10-03 2024-10-03 PlS Planned sale
2.3
Yocca Frank

Chief Scientific Officer

Officer
7,175 -20.2%
0.55
US$3,946 		7,175 -20.2% 0.55 US$3,946
2024-10-03 2024-10-03 PlS Planned sale
Rodriguez Javier

See Remarks

Officer
6,863 -22.4%
0.55
US$3,775 		6,863 -22.4% 0.55 US$3,775
2024-10-03 2024-10-03 PlS Planned sale
2.7
Steinhart Richard I

Chief Financial Officer

Officer
7,175 -26.1%
0.55
US$3,946 		7,175 -26.1% 0.55 US$3,946
2024-10-03 2024-10-03 PlS Planned sale
Wiley Matthew T.

Chief Commercial Officer

Officer
6,272 -24.8%
0.55
US$3,450 		6,272 -24.8% 0.55 US$3,450
2024-09-17 2024-09-16 PlS Planned sale
3.3
Mehta Vimal

CEO and President

Executive Director Large shareholder
1,150 -2.2%
0.69
US$794 		1,150 -2.2% 0.69 US$794
2024-09-17 2024-09-16 PlS Planned sale
3.3
Mehta Vimal

CEO and President

Executive Director Large shareholder
832 -1.6%
0.69
US$573 		832 -1.6% 0.69 US$573
2024-09-17 2024-09-16 PlS Planned sale
2.7
Steinhart Richard I

Chief Financial Officer

Officer
356 -5.4%
0.69
US$246 		356 -5.4% 0.69 US$246
2024-09-17 2024-09-16 PlS Planned sale
Rodriguez Javier

See Remarks

Officer
345 -3.6%
0.69
US$238 		345 -3.6% 0.69 US$238
2024-09-17 2024-09-16 PlS Planned sale
Wiley Matthew T.

Chief Commercial Officer

Officer
215 -5.1%
0.69
US$149 		215 -5.1% 0.69 US$149
2024-09-17 2024-09-16 PlS Planned sale
O'Neill Vincent

See Remarks

Officer
138 -3.4%
0.69
US$95 		138 -3.4% 0.69 US$95
2024-09-17 2024-09-16 PlS Planned sale
2.3
Yocca Frank

Chief Scientific Officer

Officer
355 -2.4%
0.69
US$245 		355 -2.4% 0.69 US$245
2024-09-16 2024-09-16 PrS Proposed sale
2.3
Yocca Frank

Officer

Officer
355
0.69
US$245 		355 0.69 US$245
2024-09-16 2024-09-16 PrS Proposed sale
Wiley Matthew T.

Officer

Officer
215
0.69
US$149 		215 0.69 US$149
2024-09-16 2024-09-16 PrS Proposed sale
Rodriguez Javier

Officer

Officer
345
0.69
US$238 		345 0.69 US$238
2024-09-16 2024-09-16 PrS Proposed sale
O'Neill Vincent

Officer

Officer
138
0.69
US$95 		138 0.69 US$95
2024-09-16 2024-09-16 PrS Proposed sale
2.7
Steinhart Richard I

Officer

Officer
356
0.69
US$246 		356 0.69 US$246
2024-09-16 2024-09-16 PrS Proposed sale
3.3
Mehta Vimal

Officer

Officer
1,150
0.69
US$794 		1,150 0.69 US$794
2024-09-16 2024-09-16 PrS Proposed sale
3.3
Mehta Vimal

Officer

Officer
832
0.69
US$574 		832 0.69 US$574
2024-06-18 2024-06-17 PlS Planned sale
2.3
Yocca Frank

Chief Scientific Officer

Officer
372 -2.7%
1.28
US$476 		372 -2.7% 1.28 US$476
2024-06-18 2024-06-17 PlS Planned sale
Rodriguez Javier

See Remarks

Officer
361 -4.1%
1.26
US$456 		361 -4.1% 1.26 US$456
2024-06-18 2024-06-17 PlS Planned sale
2.7
Steinhart Richard I

Chief Financial Officer

Officer
372 -6.4%
1.26
US$470 		372 -6.4% 1.26 US$470
2024-06-18 2024-06-17 PlS Planned sale
3.3
Mehta Vimal

CEO and President

Executive Director Large shareholder
2,134 -4.3%
1.28
US$2,739 		2,134 -4.3% 1.28 US$2,739
2024-06-18 2024-06-17 PlS Planned sale
Wiley Matthew T.

Chief Commercial Officer

Officer
244 -6.5%
1.26
US$308 		244 -6.5% 1.26 US$308
2024-06-18 2024-06-17 PlS Planned sale
O'Neill Vincent

See Remarks

Officer
155 -4.2%
1.29
US$199 		155 -4.2% 1.29 US$199
2024-06-17 2024-06-17 PrS Proposed sale
Rodriguez Javier

Officer

Officer
361
1.26
US$456 		361 1.26 US$456
2024-06-17 2024-06-17 PrS Proposed sale
Wiley Matthew T.

Officer

Officer
244
1.26
US$308 		244 1.26 US$308
2024-06-17 2024-06-17 PrS Proposed sale
O'Neill Vincent

Officer

Officer
155
1.29
US$199 		155 1.29 US$199
2024-06-17 2024-06-17 PrS Proposed sale
2.3
Yocca Frank

Officer

Officer
372
1.28
US$476 		372 1.28 US$476
2024-06-17 2024-06-17 PrS Proposed sale
2.7
Steinhart Richard I

Officer

Officer
372
1.26
US$470 		372 1.26 US$470
2024-06-17 2024-06-17 PrS Proposed sale
3.3
Mehta Vimal

Officer

Officer
909
1.29
US$1,173 		909 1.29 US$1,173
2024-06-17 2024-06-17 PrS Proposed sale
3.3
Mehta Vimal

Officer

Officer
1,225
1.17
US$1,429 		1,225 1.17 US$1,429
2024-06-06 2024-06-05 S Sale
3.3
Mehta Vimal

CEO and President

Executive Director Large shareholder
126,014 -1.6%
1.58
US$199,619 		126,014 -1.6% 1.58 US$199,619
2024-06-06 2024-06-04 S Sale
3.3
Mehta Vimal

CEO and President

Executive Director Large shareholder
126,014 -1.6%
1.63
US$205,516 		126,014 -1.6% 1.63 US$205,516
2024-06-04 2024-06-04 PrS Proposed sale
2.3
BioXcel LLC

10% Stockholder

Large shareholder
252,028
1.50
US$378,042 		252,028 1.50 US$378,042
2024-04-08 2024-04-04 PlS Planned sale
Rodriguez Javier

See Remarks

Officer
1,012 -11.7%
2.64
US$2,667 		1,012 -11.7% 2.64 US$2,667
2024-04-08 2024-04-04 PlS Planned sale
2.7
Steinhart Richard I

Chief Financial Officer

Officer
1,069 -18.3%
2.64
US$2,817 		1,069 -18.3% 2.64 US$2,817
2024-04-08 2024-04-04 PlS Planned sale
O'Neill Vincent

See Remarks

Officer
165 -3.0%
2.62
US$432 		165 -3.0% 2.62 US$432
2024-04-08 2024-04-04 PlS Planned sale
3.3
Mehta Vimal

CEO and President

Executive Director
4,439 -9.2%
2.62
US$11,651 		4,439 -9.2% 2.62 US$11,651
2024-04-08 2024-04-04 PlS Planned sale
3.3
Mehta Vimal

CEO and President

Executive Director
829 -1.7%
2.62
US$2,172 		829 -1.7% 2.62 US$2,172
2024-04-08 2024-04-04 PlS Planned sale
2.3
Yocca Frank

Chief Scientific Officer

Officer
1,067 -7.7%
2.64
US$2,812 		1,067 -7.7% 2.64 US$2,812
2024-04-08 2024-04-04 PlS Planned sale
Wiley Matthew T.

CHIEF COMMERCIAL OFFICER

Officer
1,008 -25.2%
2.64
US$2,656 		1,008 -25.2% 2.64 US$2,656
2024-04-04 2024-04-04 PrS Proposed sale
2.7
Steinhart Richard I

Officer

Officer
1,069
2.63
US$2,810 		1,069 2.63 US$2,810
2024-04-04 2024-04-04 PrS Proposed sale
Rodriguez Javier

Officer

Officer
1,012
2.63
US$2,662 		1,012 2.63 US$2,662
2024-04-04 2024-04-04 PrS Proposed sale
Wiley Matthew T.

Officer

Officer
1,008
2.63
US$2,651 		1,008 2.63 US$2,651
2024-04-04 2024-04-04 PrS Proposed sale
3.3
Mehta Vimal

Officer

Officer
4,439
2.62
US$11,651 		4,439 2.62 US$11,651
Explore more

More insider trading research around BioXcel Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America